TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
Research conducted at S. Cosconati and co-authors has provided new information about tuberculosis
January 13th, 2009
"Tuberculosis is among the world's deadliest infectious diseases. APS reductase catalyzes the first committed step in bacterial Sulfate reduction and is a validated drug target against latent tuberculosis infection," researchers in the United States report. "We performed a virtual screening to identify APSR inhibitors. These inhibitors represent the first non-phosphate-based molecules to inhibit APSR," wrote S. Cosconati and colleagues. The researchers concluded: "Common chemical features lay the foundation for the development of agents that could shorten the duration of chemotherapy by targeting the latent stage of TB infection." ...
Source: TB & Outbreaks Week (2009-01-13)
|
